Galmed Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development and commercialization of a new, once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones. The company uses its proprietary first-in-class family of synthetic fatty-acid/bile-acid conjugates to improve the effectiveness of product candidates. The company’s leading product candidate, aramchol, is being developed to serve as a disease modifying treatment for fatty liver disorders. For more information, visit the company’s website at www.galmedpharma.com.